Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343365 · ClinicalTrials.gov registry record
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
A clinical trial of Incurable Disease, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT04343365 is a study of Incurable Disease that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04343365, a study of Incurable Disease, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Conditions Studied
Interventions
- OTHER Evolutionary Tumor Board (ETB)
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04343365
The ClinicalTrials.gov registry entry for NCT04343365 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Incurable Disease appearing as the primary indexed condition, and to 1 intervention - of which Evolutionary Tumor Board (ETB) is the first listed.
NCT04343365 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04343365 about?
NCT04343365 is a clinical study titled "Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board". This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
What is the current status of trial NCT04343365?
This trial is currently recruiting. The enrollment target is 35 participants. The study started on 2020-05-05. Estimated completion is 2028-03.
What conditions does trial NCT04343365 study?
This clinical trial studies the following conditions: Incurable Disease.
What interventions are being tested in trial NCT04343365?
The interventions under investigation include: Evolutionary Tumor Board (ETB) (OTHER).
Who is sponsoring clinical trial NCT04343365?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343365 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.